Last reviewed · How we verify
MB-CART2019.1 Dose level 1
MB-CART2019.1 Dose level 1 is a Biologic drug developed by Miltenyi Biomedicine GmbH. It is currently in Phase 1 development. Also known as: CD2019-targeting CAR T cells, Anti-CD2019 CAR T cells.
At a glance
| Generic name | MB-CART2019.1 Dose level 1 |
|---|---|
| Also known as | CD2019-targeting CAR T cells, Anti-CD2019 CAR T cells |
| Sponsor | Miltenyi Biomedicine GmbH |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MB-CART2019.1 Dose level 1 CI brief — competitive landscape report
- MB-CART2019.1 Dose level 1 updates RSS · CI watch RSS
- Miltenyi Biomedicine GmbH portfolio CI
Frequently asked questions about MB-CART2019.1 Dose level 1
What is MB-CART2019.1 Dose level 1?
MB-CART2019.1 Dose level 1 is a Biologic drug developed by Miltenyi Biomedicine GmbH.
Who makes MB-CART2019.1 Dose level 1?
MB-CART2019.1 Dose level 1 is developed by Miltenyi Biomedicine GmbH (see full Miltenyi Biomedicine GmbH pipeline at /company/miltenyi-biomedicine-gmbh).
Is MB-CART2019.1 Dose level 1 also known as anything else?
MB-CART2019.1 Dose level 1 is also known as CD2019-targeting CAR T cells, Anti-CD2019 CAR T cells.
What development phase is MB-CART2019.1 Dose level 1 in?
MB-CART2019.1 Dose level 1 is in Phase 1.
Related
- Manufacturer: Miltenyi Biomedicine GmbH — full pipeline
- Also known as: CD2019-targeting CAR T cells, Anti-CD2019 CAR T cells
- Compare: MB-CART2019.1 Dose level 1 vs similar drugs
- Pricing: MB-CART2019.1 Dose level 1 cost, discount & access